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Abstract
Commercial SNP microarrays now provide comprehensive and affordable coverage of the human genome. However, some
diseases have biologically relevant genomic regions that may require additional coverage. Addiction, for example, is
thought to be influenced by complex interactions among many relevant genes and pathways. We have assembled a list of
486 biologically relevant genes nominated by a panel of experts on addiction. We then added 424 genes that showed
evidence of association with addiction phenotypes through mouse QTL mappings and gene co-expression analysis. We
demonstrate that there are a substantial number of SNPs in these genes that are not well represented by commercial SNP
platforms. We address this problem by introducing a publicly available SNP database for addiction. The database is
annotated using numeric prioritization scores indicating the extent of biological relevance. The scores incorporate a number
of factors such as SNP/gene functional properties (including synonymy and promoter regions), data from mouse systems
genetics and measures of human/mouse evolutionary conservation. We then used HapMap genotyping data to determine if
a SNP is tagged by a commercial microarray through linkage disequilibrium. This combination of biological prioritization
scores and LD tagging annotation will enable addiction researchers to supplement commercial SNP microarrays to ensure
comprehensive coverage of biologically relevant regions.
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Introduction
Genome-wide association studies (GWAS) have pushed human
genetics into a new era. Advances in technology and affordability
are rapidly allowing GWAS to identify genetic variants that affect
risk for human disease (http://genome.gov/26525384). GWAS
have used microarrays that allow parallel assessment of hundreds
of thousands of single nucleotide polymorphisms (SNPs), and now
also copy number variant (CNVs). The technology of Affymetrix
(http://affymetrix.com), Illumina (http://illumina.com) and Per-
legen (http://perlegen.com) have been most often used for these
studies. While these microarrays have been designed to efficiently
explore genetic variation across the entire human genome, they
each provide better coverage in some genomic regions than in
others [1,2].
Most of the SNPs assessed by these commercial microarrays
were chosen in ways that are not based on hypotheses about the
underlying biology of any particular disorder. However, to the
extent that there is a body of knowledge concerning the biology of
a disorder, not all genes may be as likely, a priori, to contain disease
associated variants. Thus, if a commercial microarray is used for a
GWAS, we might ask – how well does the microarray cover
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5225biologically relevant genes for which there is a priori reason to
believe their products are involved in the disease of interest [3]?
For example, because genes that encode nicotinic cholinergic
receptors have a clear biochemical connection to nicotine
dependence, as do alcohol dehydrogenases for alcoholism, we
should be especially vigilant in testing the hypothesis that variants
in these genes might influence addiction vulnerability.
We have assembled data concerning the biology of addiction in
order to examine the genomic coverage of commercial SNP
microarrays. We show that several of these arrays, including top of
the line models such as the Illumina 1M and Affymetrix 6.0, fail to
cover a significant amount of common genetic variation in
addiction-related genes. We have also developed a SNP database
that can be used to supplement these microarrays to achieve
comprehensive coverage of these regions. This database is
annotated with numeric prioritization scores [4] indicating the
biological relevance of a SNP to addiction. This allows the
prioritization of supplementary SNPs when resources are limited.
We also include annotation indicating the extent to which a SNP is
tagged through linkage disequilibrium (LD) with some SNP on a
specific array with respect to a specific HapMap population:
African, Chinese, European-American and Japanese. By combin-
ing the prioritization scores with LD tagging data, we can
determine the most biologically relevant SNPs for comprehensive
LD tagged coverage of genes that are biologically relevant to
addiction.
Results
Table 1 shows the number of supplementary SNPs needed to
tag all common variants in various populations for our primary set
of 910 genes that are biologically relevant to addiction. This set
includes 486 genes that were derived mainly through an expert
nomination process, and 424 additional genes that correspond to
roughly the top 5% of genes identified using mouse systems
genetics (Chesler and colleagues, submitted). Together this set of
910 genes was our primary set for the analysis of microarray
coverage (see supporting file S1 for the complete list of these
genes). We assessed the SNP coverage of these genes by
determining if common SNPs (MAF$5%) were tagged through
LD by SNPs on a particular microarray. In Table 1, for each array
and each population, we report the number of common SNPs in
these genes that fail to satisfy r
2$0.8 with a SNP from the array;
that is, the number of SNPs not tagged by the array. For example,
we found that 57% of the common SNPs in these genes were not
tagged by the Affymetrix 5.0 SNP microarray in the African
population. In other words, due to the haplotype/LD structure in
the African population, 43% of the common genetic variation in
these regions fails to be captured by this microarray. Table S1
gives a broader view of how microarray coverage depends on
biology, and shows that the Illumina coverage tends to improve
with the prioritization score, while the Affymetrix coverage is
uniform.
These results suggest that a significant amount of common
genetic variation in these addiction related genes is unaccounted
for by these commercial SNP microarrays. The deficiency is
particularly high in the African sample. This is likely due to the
lower LD in this older population, which means more SNPs are
required for tagging. While the Illumina 1M clearly provides the
best coverage, we would still need to add 23,441 SNPs to tag all
common SNPs in the HapMap African sample for these 910
genes. The best-case scenario is when the Illumina 1M is used for
European-Americans. But even in this case, there are still 5,117
SNPs that are not well represented.
Table 2 shows some examples of coverage by the Illumina 610
Quad microarray for ten genes that are of particular interest. We
chose this array because it offers a median level of coverage among
the seven arrays we studied. These genes were among the most
highly prioritized by the addiction researchers with whom we
consulted. The selection process involved a number of criteria,
including pharmacogenetic pathways, gene expression data, and
mouse models. For example, CDH13 (Cadherin 13) is known to be
expressed in neurons in the human adult cerebral cortex,
midbrain, thalamus and medulla regions [5]. Because it is also
known to inhibit neurite extension [6] and activate a number of
signaling pathways [7–10], it is a strong candidate for the genetic
study of addiction phenotypes [11]. CDH13 contains 2,414 SNPs
that are common in the African population, and only 50% of these
are tagged by the by the Illumina 610 Quad microarray. Figure S1
shows the complete distribution of individual gene coverage
percentages using our primary set of 910 genes for the Illumina
610 Quad microarray in each population.
Table 1. The number of SNPs required to supplement commercial microarrays in order to comprehensively cover our primary set
of 910 genes that are biologically relevant to addiction.
Number of Supplementary SNPs (%)
African Chinese European-American Japanese
All Common SNPs: 86,925 73,241 79,274 72,843
Microarray
Affymetrix 5.0 49,762 (57) 24,691 (34) 28,001 (35) 24,183 (33)
Affymetrix 6.0 27,945 (32) 11,499 (16) 12,542 (16) 11,132 (15)
Illumina 300 Duo 56,475 (65) 22,821 (31) 16,364 (21) 22,934 (31)
Illumina 550 37,776 (43) 10,166 (14) 7,362 (9) 9,962 (14)
Illumina 610 Quad 36,448 (42) 10,064 (14) 7,324 (9) 9,845 (14)
Illumina 650Y 29,417 (34) 9,396 (13) 7,062 (9) 9,105 (12)
Illumina 1M 23,441 (27) 6,370 (9) 5,117 (6) 6,056 (8)
Results are listed for four populations. The numbers in parentheses are the percentages of all common SNPs in these genes in the corresponding population. For
example, there are 86,925 SNPs in these genes with MAF$5% in the African population, and we found that 57% of these SNPs fail to satisfy r
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wustl.edu/nida/neurosnp.html) to systematically determine how
to supplement these commercial microarrays for addiction. Our
database includes a SNP prioritization score based on the genomic
information network (GIN) method introduced by S. Saccone and
colleagues [4]. This method was originally designed to systemat-
ically incorporate a priori biological hypotheses into the prioritiza-
tion of SNPs after a genome-wide association study. The method
begins with a set of SNPs that are ranked by their association p-
values, and then increases the rank of a SNP when it is determined
to be biologically relevant to the phenotype according to an a priori
set of conditions, such as being in a biologically relevant gene, and
additionally, perhaps, being a missense mutation. The score is a
measure of biological relevance to addiction, and can be used
independently of association p-values to prioritize which SNPs are
selected to supplement commercial microarrays. The score
incorporates SNP/gene functional properties (such as coding
and promoter regions), human/mouse evolutionary conservation,
and a quantitative trait locus (QTL) mapping method that utilizes
mouse models to identify genes associated with addiction
phenotypes (Chesler and colleagues, submitted). Figure S2 shows
the distribution of prioritization scores for our genome-wide SNP
database, and Figure S3 shows the GIN network model we used to
model addiction, which was adapted from the nicotine depen-
dence model used by Saccone and colleagues [4].
In addition to our primary set of 910 genes, the mouse systems
genetics method (Chesler and colleagues, submitted) that identified
7,842 additional genes with potential biological relevance to
addiction through mouse QTL and gene expression correlation
analysis and the GIN prioritization scores reflect this quantitative
assessment of biological relevance. Genes with a large number of
mouse associations are prioritized more highly, and those with a
relatively low number receive little increase in the prioritization
score relative to arbitrary genes (see the methods section for
details). These additional data provide a broader measure of
biological relevance to addiction which may be useful for
prioritizing SNPs for further study after a GWAS [4] or fine
mapping a region of genetic linkage. This method has the effect of
combining information from the expert nomination process and
the mouse systems genetics data. SNPs in the 486 expert
nominated genes, the determination of which did not involve the
mouse data, receive a uniform increase in priority. If there is
additional evidence from the mouse data of relevance of the gene
to addiction, the priority is increased further depending on the
extent of the evidence, which is measured by the number of mouse
phenotypes that link to the gene.
Table S2 shows the distribution of phenotypes that map to
mouse genes, both for the entire set of mouse genes considered and
for the top 424 genes that were used for our primary analysis of
SNP microarrays (these were mapped to human genes via NCBI
Homologene). More detailed information on this latter set of genes
can be found in supporting file S1 which is discussed in more detail
below. Complete details on the data and experiments for this
mouse systems genetics project are described in Chesler and
colleagues (submitted).
In order to determine the coverage of regions inferred to be
undergoing recent adaptive selection [12,13], all SNPs detected by
the LD decay (LDD) test in the Perlegen and HapMap datasets
were compared to the Illumina 1M and Affymetrix 6.0 SNPs.
Uncovering evidence for recent selection is an additional approach
to defining functional human genomic variation. The LDD test
identifies alleles undergoing selection by searching for an expected
increase with distance in the fraction of inferred recombinant
chromosomes surrounding a selected variant. This method is
insensitive to local recombination rate because it relies on LD
differences between the two alleles at a site, while the local rate
influences the extent of LD surrounding both alleles. While over
99.9% of the selected regions defined by the LDD test fall within
+/210 kb of a SNP present on these microarrays, there are some
important exceptions. For example, the extensive LD surrounding
the selected DRD4 7R allele [14] is not captured by these arrays,
which contain very few SNPs in the region (only 1 in 100 kb). In
general, however, the extensive long-range LD exhibited by these
recently selected alleles (up to 1 Mb), and the current density of
microarray SNPs, indicates that most of these evolutionarily
important alleles can be ‘‘tagged’’ by an adjacent SNP surrogate.
The combined set of 910 genes used for our analysis of SNP
microarrays is available as a spreadsheet in supporting file S1. The
spreadsheet contains detailed annotation, including the logical
category used by the NeuroSNP project, such as ‘‘Nicotine System’’
and ‘‘Dopamine System’’ (further documentation of these categories
and other columns is contained in the spreadsheet – see the sheet
labeled ‘‘Column Descriptions’’). Other columns include the Entrez
Gene ID and gene symbol, the full name of the gene as well as all
known symbol aliases and alternative descriptions, build 36.2 physical
mapping data and mouse homologs. Some columns contain links to
external databases, such as GenoPedia (http://www.hugenavigator.
net/HuGENavigator/startPagePedia.do), which contains a list of all
human diseases that have been linked to the gene, including links to
publications. The spreadsheet also contains links to the Knowledge-
base of Addiction Related Genes (KARG, http://karg.cbi.pku.edu.
cn) [15], and also GeneNetwork (http://genenetwork.org) for
additional information on mouse systems genetics data. We have
also created a web site (http://zork.wustl.edu/nida/neurosnp.html)
that contains a searchable database of this set of genes, as well as
downloadable files for the gene and SNP databases. These resources
willallow investigatorsto both gathernewbiologically relevant targets
for genetic association studies of addiction, and also to discover new
information on well-known targets, such as the extent of tagged
coverage in various population by commercial SNP microarrays.
Our complete SNP database is available for download from our
web site at http://zork.wustl.edu/nida/neurosnp.html, and the
top 5,000 SNPs ranked by GIN prioritization score [4] is provided
in a spreadsheet as supporting file S2. The entire database includes
Table 2. The number of SNPs required to supplement the
Illumina 610 Quad microarray for genes of particularly strong
interest.
Gene Number of Supplementary SNPs (%)
African Chinese European-American Japanese
CDH13 1,207 (50) 417 (21) 340 (15) 389 (20)
CHRNA3 7 (28) 2 (9) 0 0
CHRNA5 4 (15) 1 (5) 0 4 (21)
CHRNB4 4 (33) 5 (38) 3 (23) 5 (38)
COMT 11 (48) 4 (17) 4 (20) 3 (13)
GABRA2 32 (29) 5 (5) 8 (8) 5 (5)
MAPK1 20 (33) 7 (10) 0 16 (24)
OPRM1 90 (40) 20 (14) 16 (6) 13 (7)
SLC1A2 82 (36) 12 (5) 7 (3) 19 (9)
SLC7A11 19 (48) 7 (28) 7 (21) 3 (10)
The numbers in parentheses are the percentages of all common SNPs in these
genes in the corresponding population.
doi:10.1371/journal.pone.0005225.t002
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frequency data from the four HapMap samples; there is no
restriction on the allele frequency in the database. There are also
flags indicating whether a SNP is on a particular custom
microarray specifically designed by Hodgkinson and colleagues
to target alcoholism and other addiction related phenotypes [16],
or was part of an addiction study by Nielsen and colleagues [17].
Discussion
We have found that in order to achieve comprehensive tagged
coverage of genes that are biologically relevant to addiction in the
African, Chinese, European-American and Japanese populations,
all the commercial SNP microarrays we considered require
significant supplementation. The approaches used here will aid
other investigators to supplement these arrays, to target specific
genomic regions such as genes and linkage regions, and also
improve the general selection of SNPs for genetic studies of
addiction based on the ‘‘biological role in addiction’’ criterion.
The development of a database of addiction related genes is
similar to existing methods and resources in the literature [15–17],
the primary difference being our development of a SNP database
and a prioritization algorithm that allows the systematic
supplementation of commercial SNP microarrays.
These methods and resources were developed with the intention
that they would be useful to researchers who wish to test ap r i o r i
biological hypotheses, either within the context of a GWAS, or for a
more targeted study such as studying specific addiction-related genes
or fine mapping a region of genetic linkage for an addiction-related
phenotype. The need for this kind of approach has been discussed in
the literature [3], and to this end we have used multiple domains to
develop a collection of genes with evidence of biological relevance to
addiction. The biological principles guiding the selection criteria,
such as biochemical pathways and expression data, do not necessarily
imply the existence of genetic variants within these genes that
influence addiction phenotypes. For example, metabolic pathways
related to nicotine are an obvious source for cataloging genes that are
biologically relevant to genetic studies of nicotine dependence, but
these normal biological systems do not necessarily involve genes with
variants that influence abnormal phenotypes. Therefore, the utility of
these methods and resources depend on the subjective preferences of
investigators on the genetics of addiction and their specific ap r i o r i
biological hypotheses [3].
W h i l et h ep r i m a r yu t i l i t yo ft h er e s o u r c ew eh a v ed e v e l o p e di st h e
supplementation of commercial SNP microarrays, it has several other
useful applications. For example, the GIN prioritization scoring
method is useful for interpreting the results of a GWAS, and can be
used to prioritize SNPs for further study after a GWAS [4], as well as
prioritize tests of gene-gene interaction. As the genomic coverage of
commercial SNP microarrays improves, and subsequently whole-
genome sequencing becomes the new standard, the problem of
multiple testing will continue to hinder progress in understanding
complex interactions underlying the genetics of addiction and other
complex diseases. Therefore tests of gene-gene interaction will in
most cases require a mechanism of prioritization, and our database
will be a useful resource for this approach. By limiting tests of gene-
gene interaction to genes that have a biological connection to the
phenotype, the issues of multiple testing and computational
tractability are substantially reduced. And even within a set of
biologically relevant genes, using the GIN prioritization scores to
further refine interactions tests, such as testing only within the top 100
SNPs ranked by these scores, will further reduce the problem.
Table 1 shows that a substantial amount of variation in high
priority regions for addiction is currently unaccounted for by these
commercial microarrays. Ultimately, the actual number of SNPs
used to supplement a microarray will depend on the genotyping
platform being used for supplementation. This platform could
involve a different technology than that of the original microarray
being supplemented. For example, the Affymetrix 6.0 array could
be supplemented with custom genotyping on the Illumina
GoldenGate platform (http://www.illumina.com), and because
some of the SNPs used for Table 1 may not perform well on the
GoldenGate platform, the numbers reported in the table may need
to be reduced.
Our results highlight the need to supplement commercial SNP
microarrays for genetic studies of addiction in order to have
adequate coverage for genes in relevant neurobiological pathways.
Our SNP database will help researchers to fill the missing gaps by
providing a quantitative measure of biological relevance to help
prioritize SNPs for supplementation. Addiction researchers should
find this resource to be a valuable tool, both in the design and
interpretation stages of a GWAS. It helps prioritize coverage of
biologically relevant regions, and highlights association signals in
those regions when selecting SNPs for replication. It also helps
prioritize tests of gene-gene interaction, which can limit multiple
testing issues. In this study the focus was on addiction, but our
method can be extended to other diseases by creating a new
database of biologically relevant genes.
Methods
We assembled a list of 486 genes biologically relevant for addiction
mainly through an expert nomination process (http://grants.nih.
gov/grants/guide/notice-files/NOT-DA-07-010.html). Most of
these were identified based on involvement in neurobiological
pathways relevant to substance abuse and were in part vetted by
addiction neurobiologists (see Acknowledgments). These included
genes involved in biosynthesis, metabolism, transport, receptor
binding, and intracellular signaling. Common biochemical pathways
and systems included the serotonergic, noradrenergic, dopaminergic,
GABA-ergic, glutamatergic, opioid, alcohol metabolizing and
nicotinic systems. In addition, genes involved in the metabolism of
FDA-approved medications for substance abuse were also included
(e.g., cytochrome p450 genes); genes involved in the medications’
pharmacodynamic effects were selected as part of the pathway-based
approach. 34 of these genes were added to the initial results of the
nomination process because they used for recent custom panel of
SNPs for alcoholism and other addiction related traits [16], and 96 of
these genes were added from a recent study of addiction [17].
An additional 424 genes were nominated based on behavioral
genetic analysis of 255 measures of addiction related phenotypes
obtained by the Tennessee Mouse Genome Consortium in the
recently expanded panel of over 60 BXD recombinant inbred
mouse lines (Chesler and colleagues, submitted). Because we are
interested in identifying addiction associated pathway members
that are polymorphic in humans, but not necessarily polymorphic
in mice, our approach identified both candidate genes for mouse
phenotypic variation, and biomolecular correlates of the mouse
phenotypes. Each gene was chosen because it either resided in a
significant or suggestive QTL interval or was a gene expression
correlate of multiple addiction-related phenotypes. The criteria
used to place genes on the list included correlations with p,.0001,
and QTLs, with genome-wide permutation p,.05 or p,.33, the
conventional thresholds for significant and suggestive loci.
Convergence of evidence of these effects in multiple addiction
assays was the criteria used for list membership. Mouse genes were
then mapped to human genes via the HomoloGene database
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=homologene).
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genes, we created a general purpose genome-wide SNP relational
database. The foundation for this database was Build 128 of
dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP), which was
our source of physical mapping data and SNP/gene functional
properties. We then examined the SNP coverage of these genes as
provided by seven commercial microarrays: the Illumina Human-
Hap300 Duo, HumanHap550, HumanHap650Y and Human1M
(http://www.illumina.com), and the Affymetrix Genome-Wide
Human SNP Array 5.0 and 6.0 (http://www.affymetrix.com). To
assess genomic coverage of common SNPs by these microarrays,
we used genotype data for four populations from the International
HapMap Project, Public Release 23a (http://www.hapmap.org):
African (Yoruba people of Ibidan, Nigeria – YRI), Chinese
(Beijing – CHB), European-Americans (CEPH – CEU), and
Japanese (Japan – JPT). To estimate LD, we used the program
HaploView (version 4.0, http://www.broad.mit.edu/mpg/haplo-
view) [18] to estimate r
2 for all SNPs within 500 kb of each other.
The commonly used condition r
2$0.8 was used to assess whether
a SNP is tagged through LD in a given population by a given SNP
microarray. General database management was done with a
combination of SAS [19] and Perl [20].
To provide a mechanism for prioritizing SNPs when supple-
menting SNP microarrays for addiction, we used the genomic
information network (GIN) technique introduced by Saccone and
colleagues [4]. The GIN method assigns each SNP a numeric
prioritization score indicating the biological relevance for
addiction: the higher the score, the greater the priority. Figure
S3 shows the network model we used for addiction, which is a
modification of the nicotine dependence model used by Saccone
and colleagues. The score incorporates a number of factors,
including SNP/gene functional properties (such as coding and
promoter regions), and evolutionary conserved regions (ECRs,
provided by ECRbase [21], http://ecrbase.dcode.org). The
original GIN method introduced by Saccone and colleagues
incorporated LD into the prioritization score through the use of
LD proxies. This is more appropriate when prioritizing SNPs for
replication after an initial GWAS. In our current implementation,
where we are selecting SNPs to supplement arrays for the
discovery phase of a GWAS, we have eliminated the LD
component in order to avoid redundancy among the selected
SNPs.
The scoring method is identical to Saccone and colleagues [4]
for the gene and ECR nodes. The ‘‘Addiction Systems’’ node adds
1 to the score for any of the 486 genes from our expert nomination
process. The score for the ‘‘Mouse QTL Mapping’’ node is
min(N/6,1), where N is the number of phenotypes identified for a
gene using the systems genetic methods. This means that the score
is 1 for all genes where N is greater than 6, which corresponds to
the top 5% of QTL mapping results. The score is scaled down
linearly when N is less than 6. Note that this particular GIN model
combines information from the expert nomination process and the
mouse systems genetics data in the sense that SNPs in the 486
expert nominated genes, the determination of which did not
involve the mouse data, would receive an increased score if there
was additional evidence from the mouse data of relevance to
addiction.
Supporting Information
Table S1 The coverage of genomic regions biologically relevant
to addiction in four commercial SNP microarrays. The table is
divided into direct coverage, the percentage of common SNPs
actually on the array, and tagged coverage, the percentage of
common SNPs tagged by an array through LD at r
2$0.8 in the
specified HapMap population (for simplicity, we used only two
populations). We explore how coverage varies with biological
relevance by considering SNPs with a GIN prioritization score
greater than a given threshold: the larger the score, the greater the
biological relevance. For direct coverage, common SNPs must
have a MAF of at least 5% in one of the HapMap populations. For
tagged coverage, SNPs must satisfy this condition in the specified
population.
Found at: doi:10.1371/journal.pone.0005225.s001 (0.06 MB
DOC)
Table S2 Results of the systems genetics study to identify mouse
genes related to addiction. For each trait the table shows the
overall number of genes identified by QTL and gene expression
analysis. For our analysis of SNP microarray coverage we used the
top 5% from the mouse systems genetics project ranked by the
number of phenotypes linked to each gene. The third column
shows the number of genes from the top 5% identified for each
trait.
Found at: doi:10.1371/journal.pone.0005225.s002 (0.06 MB
DOC)
Figure S1 The number of genes biologically relevant to
addiction that require varying amounts supplementary coverage
for the Illumina 610 Quad microarray. Here we consider our
primary set of 910 genes. The horizontal axis shows the
percentage of SNPs in the gene not tagged by the array in the
corresponding population. For example, in the African population,
there are 35 genes (3.97%) where at least 90% of the SNPs in those
genes are not tagged by this array with r
2$0.8 (the rightmost bar
in the histogram).
Found at: doi:10.1371/journal.pone.0005225.s003 (0.12 MB
DOC)
Figure S2 The distribution of the prioritization scores S from
the genomic information network (GIN) for addiction. We
considered all known SNPs using dbSNP build 128. The score is
a cumulative measure of biological relevance based on several
factors: our expert nomination process for genes related to
addiction, SNP/gene functional properties, human/mouse evolu-
tionary conservation, and mouse QTL mapping methods. For
example, SNPs with a score of 0 are not in genes, and are not in
LD with a gene or human/mouse evolutionary conserved region
with 500 Kb. SNPs in genes have a score of at least 1. The score
increases if the gene is biologically relevant to addiction, and
increases further depending on the number of mouse QTLs for
that gene, and also the functional properties of SNP, such being
nonsynonymous or being in a promoter region.
Found at: doi:10.1371/journal.pone.0005225.s004 (0.05 MB
DOC)
Figure S3 The genomic information network (GIN) model for
addiction. The network represents the process of determining a
numeric prioritization score for a SNP. The scores are a
cumulative measure of biological relevance using SNP/gene
functional properties (the Gene node), evolutionary conserved
regions (the ECR node), genes biologically relevant to addiction
(the Addiction Systems node), and mouse QTL mapping results.
The overall GIN prioritization scores can be used to prioritize
SNPs when supplementing commercial microarrays for addiction.
Found at: doi:10.1371/journal.pone.0005225.s005 (0.05 MB
DOC)
File S1 This workbook contains two sheets: (1) an annotated
sheet with the primary set of 910 genes used for analysis (2) a list of
column descriptions
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File S2 This workbook contains two sheets: (1) an annotated
sheet with the top 5,000 SNPs ranked by prioritization score (2) a
list of column descriptions
Found at: doi:10.1371/journal.pone.0005225.s007 (3.76 MB
XLS)
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